Form 4: Ardelyx CAO Joseph Reilly Executes Sell-to-Cover Trade
Insider Transaction Report
Ardelyx, Inc. Chief Accounting Officer Joseph J. Reilly sold 3,719 shares of common stock to satisfy tax obligations related to RSU vesting.
Summary
- Joseph J. Reilly, Senior Vice President and Chief Accounting Officer of Ardelyx, Inc., sold a total of 3,719 shares of common stock on May 21, 2026.
- The shares were sold at a price of $6.2675 per share.
- The transaction was executed as an automatic sell-to-cover to satisfy tax withholding obligations resulting from the vesting of restricted stock units (RSUs).
- Following the transaction, the reporting person maintains beneficial ownership of 149,107 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and required to satisfy tax obligations rather than a discretionary divestment.
Positives
- The transaction was non-discretionary and mandated by the terms of the original RSU grant, indicating it was not a signal of negative sentiment regarding company performance.
Negatives
- The sale reduces the direct equity stake held by a key member of the financial leadership team.
Risks
- None identified; this is a routine tax-related transaction.
Future Outlook
No forward-looking guidance provided in this filing.
Industry Context
StockSavvy.ai notes that sell-to-cover transactions are standard practice in the biotechnology sector, where equity compensation is a significant component of executive remuneration. These filings are administrative in nature and do not typically reflect management's outlook on the company's clinical or commercial progress.
Comparison to Industry Standards
- The transaction aligns with standard corporate governance practices for handling tax withholding on equity awards.
- The behavior is consistent with typical executive compensation structures at mid-cap biotech firms like Ardelyx.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was a pre-planned tax-related sale.
Next Steps
- No future actions or milestones mentioned.
Key Dates
| Date | Description |
|---|---|
| 2026-02-27 | Date of acquisition of 1,765 shares under the employee stock purchase plan. |
| 2026-05-21 | Date of the reported sell-to-cover transaction. |
| 2026-05-22 | Date of filing. |
Keywords
Ardelyx, ARDX, Form 4, Insider Trading, Sell-to-cover, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.